It is unknown whether the combination treatment with IL-2 and a calcineurin inhibitor can selectively induce Treg expansion while inhibiting pathogenic Tfh expansion and exerting additive effects in SLE treatment. The gene discussed is IL2; the disease is systemic lupus erythematosus.